Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Comphya logo — Providing a better solution for non-responders to oral drugs...

Comphya

Providing a better solution for non-responders to oral drugs.

Founded 2017 Switzerland Ecublens, Switzerland 7 employees Convertible Note Total: $5.28M Biotechnology, Health Care +1

General Information

Company Name Comphya
Founded Year 2017
Location Switzerland Ecublens, Switzerland
Employees 7
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Convertible Note
Social

BounceWatch is an independent company data service, not affiliated with Comphya. To contact Comphya, visit comphya.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Comphya compare?

A PDF of Comphya and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Comphya soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Comphya

Comphya is an innovative medical device startup founded in 2017, specializing in the development of the CaverSTIM device. The company's flagship product, CaverSTIM, utilizes cutting-edge neuroprosthetics expertise to restore erectile function in patients who do not respond to oral drugs. This groundbreaking technology involves implanting a neuro-stimulator in the pelvic cavity to selectively activate the nerve responsible for triggering penile erection. CaverSTIM comprises an implantable pulse generator (IPG), connected to an electrode paddle, external controllers for patients and physicians, and a wireless recharger. The company has garnered significant attention, receiving a Fr.850.00KConvertible Note investment on 31 January 2023 from Praxis Spinal Cord Institute. Comphya operates in the Biotechnology and Health Care industries and holds great potential in addressing an unmet medical need for patients struggling with erectile dysfunction.

Business keywords: Neuroprosthetics, Erectile Dysfunction Treatment, Neuro-stimulator, Implantable Pulse Generator, Healthcare Innovation, Medical Technology, Neuroscience, Healthcare Devices, Innovative Healthcare Solutions

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note Fr.850.00K 1
Praxis Spinal Cord Institute.
Praxis Spinal Cord Institute.
31 Jan 2023
Convertible Note $1.30M 1
Foundation for Technological Innovation (FIT)
01 Dec 2020
Seed Round Fr.3.00M 3
Verve Ventures Nest Collective Foundation
Verve Ventures, Nest Collective Foundation +1
26 Jun 2019
Debt Financing Fr.100.00K 1
Foundation for Technological Innovation (FIT)
30 Nov 2017
Grant Fr.20.00K 1
Venture Kick
Venture Kick
05 Sep 2017
Grant Fr.10.00K 1
Venture Kick
Venture Kick
06 Jun 2017

Latest News

View All
Dutch Men’s health startup Fellos lands €2 million to tackle sensitive issues like ED and PE through... — Eu-startups
Dutch Men’s health startup Fellos lands €2 million to tackle sensitive issues like ED and PE through telehealth
Eu-startups Oct 07, 2025

Comphya Alternatives & Competitors

View All Alternatives
Comphya vs
Akili
Akili United States

Play your medicine®

Series D
124 employees
Biotechnology, Health Care
Comphya vs
Phagenesis Ltd
Phagenesis Ltd United Kingdom

Dysphagia therapy like no other!

Series D
44 employees
Biotechnology, Health Care
Comphya vs
CVRx | Barostim
CVRx | Barostim United States

CVRx’s Barostim is a breakthrough technology that stimulates the body’s natural baroreflex to treat...

Private Equity
246 employees
Biotechnology, Health Care
View all alternatives

FAQ About Comphya

Providing a better solution for non-responders to oral drugs.
Comphya was founded in 2017.
Comphya is headquartered in Ecublens, Switzerland.
Comphya operates in Biotechnology, Health Care and Life Sciences. Its work centres on Neuroprosthetics, Erectile Dysfunction Treatment, Neuro-stimulator and Implantable Pulse Generator.
Comphya has approximately 7 employees.
Comphya has completed 6 funding rounds, raising a total of $5.28M. The latest funding stage is Convertible Note.
Top alternatives and competitors to Comphya include Akili, Phagenesis Ltd, CVRx | Barostim, ImThera Medical, now a part of LivaNova, Cameron Health. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Comphya and Akili are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Comphya, https://bouncewatch.com/company/comphya, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout